Literature DB >> 20103322

Minimally invasive transapical aortic valve implantation and the risk of acute kidney injury.

Justus T Strauch1, Maximilian P Scherner, Peter L Haldenwang, Roman Pfister, Elmar W Kuhn, Navid Madershahian, Parwis Rahmanian, Jens Wippermann, Thorsten Wahlers.   

Abstract

BACKGROUND: The new technique of minimally invasive transapical aortic valve implantation (TAP-AVI) deals with high-risk patients and despite the absence of cardiopulmonary bypass it might lead to renal impairment. The aim of this study was to estimate the risk of the development of acute kidney injury (AKI) after TAP-AVI and to identify possible risk factors with regard to the morbidity and mortality of the patients.
METHODS: Data of 30 consecutive patients undergoing TAP-AVI were recorded and followed up for 8 weeks. Postoperative AKI has been defined according to RIFLE criteria. Two patients on chronic hemodialysis have been followed up.
RESULTS: Of 28 patients, AKI occurred in 16 patients (57%). Statistical analysis revealed no influence on the risk of developing AKI caused by the dose of applicated contrast medium (p = 0.09), the patient's age (p = 0.5), or the existence of diabetes (p = 0. 16). Analysis concerning the relationship between a preexisting coronary heart disease and AKI showed a tendency to be associated with a higher risk of the development of AKI (70% preexisting congenital heart disease in the AKI group versus 50%; p = 0.28). Only a preoperative serum creatinine greater than 1.1 mg/dL was a strong predictor for developing AKI (p < 0.01). Length of stay in the intensive care unit and the complete length of hospital stay revealed no difference with regard to postoperative development of AKI though statistical analysis showed a trend to a higher mortality in the AKI group (27% vs 6%); univariate analysis did not reach statistical significance (p = 0.13).
CONCLUSIONS: The TAP-AVI seems to be a feasible procedure for high-risk patients with a clear risk of developing AKI. Patients at risk should be identified and, if indicated, already preoperatively treated in collaboration with the attending nephrologists. 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103322     DOI: 10.1016/j.athoracsur.2009.09.090

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  A systematic review of transapical aortic valve implantation.

Authors:  Mohammad Rahnavardi; Jaime Santibanez; Karan Sian; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2012-07

Review 2.  Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis.

Authors:  Wim Vandenberghe; Sofie Gevaert; John A Kellum; Sean M Bagshaw; Harlinde Peperstraete; Ingrid Herck; Johan Decruyenaere; Eric A J Hoste
Journal:  Cardiorenal Med       Date:  2015-12-19       Impact factor: 2.041

Review 3.  Acute kidney injury post-transcatheter aortic valve replacement.

Authors:  Pradhum Ram; Kenechukwu Mezue; Gregg Pressman; Janani Rangaswami
Journal:  Clin Cardiol       Date:  2017-12-18       Impact factor: 2.882

4.  TOPK Activation Exerts Protective Effects on Cisplatin-induced Acute Kidney Injury.

Authors:  Hui Zhang; Qing-Qing Dong; Hua-Pan Shu; Yu-Chi Tu; Qian-Qian Liao; Li-Jun Yao
Journal:  Curr Med Sci       Date:  2022-06-09

5.  Risk Assessment of Patients Undergoing Transfemoral Aortic Valve Implantation upon Admission for Post-Interventional Intensive Care and Surveillance: Implications on Short- and Midterm Outcomes.

Authors:  Fadi Al-Rashid; Philipp Kahlert; Friederike Selge; Heike Hildebrandt; Polycarpos-Christos Patsalis; Matthias Totzeck; Petra Mummel; Tienush Rassaf; Rolf Alexander Jánosi
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

6.  Transcatheter aortic valve implantation in patients with pre-existing chronic kidney disease.

Authors:  Mohammed Shamim Rahman; Rajan Sharma; Stephen J D Brecker
Journal:  Int J Cardiol Heart Vasc       Date:  2015-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.